NICE has been told by its appeal panel to reconsider its draft decision rejecting the use of growth hormone in adults.
The move comes after the panel backed a number of appeals by eight organisations including three drug companies.
It is believed that NICE had rejected the product because of a lack of clinical evidence and limited cost effectiveness.
תגובות רוצה להצטרף לדיון?
יש להתחבר כדי להגיב.
התחבראין תגובות עדיין. היה הראשון להגיב!